Changing trends in HER-2 neu positive breast cancers in women: A study by a medical student and his preceptor.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12509-e12509
Author(s):  
Aaron Monga ◽  
Chaya Prasad ◽  
Rama Prasad ◽  
Rita Alcantara
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Metastatic Breast ◽  
The United States ◽  
Histologic Grade ◽  
Prognostic Indicators ◽  
Lymph Node Status ◽  
Low Grade ◽  
Breast Cancers ◽  
Her 2

e12509 Background: Breast cancer affects 3.5 million women in the United States with 155, 000 women living with metastatic breast cancer in the US with 40,290 deaths every year. In particular, HER-2 NEU positive lesions are aggressively malignant, with increased recurrence and decreased survival but good response to Herceptin. This study reviews trends of breast cancers and looks in depth into prognostic indicators, in HER-2 NEU positive breast cancers. Methods: Anonymized medical data including demographics and tumor characteristics from San Antonio Regional Hospital’s (SARH) tumor registry database were collected from 2015-2017. Inclusion criteria included female patients with a diagnosis of invasive breast cancers. Data was stratified according to age at diagnosis, race of the patient, histologic grade, size of the tumor, lymph node status, HER-2 NEU status and stage (pathologic and clinical). Results: From 2015 to 2017 we identified 371 patients with invasive breast cancers. The percentages of HER-2 NEU positive patients in these years was 15.7%, 16.0%, and 9.4% in 2015, 2016 and 2017 respectively. This represented a 6.6% drop in HER-2 NEU positive patients from 2016 to 2017. We then looked at all HER-2 NEU positive breast cancers. In 2017, 71% of patients with HER-2 NEU positive tumors presented with a low pathologic size compared to 36% in 2016 and 44% in 2015, and 29% presented with low histologic grade compared to 14% in 2016 and 12% in 2015, and 0% of patients presented with lymph node metastases compared to 18% in 2016 and 20% in 2015. Overall 100% of patients with HER-2 NEU positive tumors presented at a low stage compared to 73% in 2016 and 52% in 2015. Conclusions: Our data shows a decrease in HER-2 NEU positive cancers from 2015 to 2017. It is important to note that these HER-2 NEU lesions were associated with, smaller pathologic size, lower histologic grade, lower incidence of lymph node involvement and lower clinical stage. The identification of this subset of low grade, low stage HER-2 NEU positive tumors may be attributed to newer imaging modalities such as digital tomosynthesis and more aggressive preventive screening measures. These sensitive screening techniques may ensure a good clinical outcome.

HER-2, Hormone Receptors, and clinicopathologic characteristics in Uruguayan breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22202-e22202
Author(s):  
L. B. Delgado ◽  
R. Fresco ◽  
G. Santander ◽  
S. Aguiar ◽  
N. Camejo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Axillary Lymph Node ◽  
Triple Negative ◽  
Histologic Grade ◽  
Her2 Status ◽  
Lymph Node Status ◽  
Axillary Lymph ◽  
Axillary Lymph Node Status ◽  
Her 2

e22202 Background: Few Latin-American studies and none Uruguayan study have evaluated HER-2, estrogen receptor (ER) and progesterone receptor (PR) in breast cancer (BC). The purpose of the study was to investigate the frequency of these markers and the relationship between them and with clinicopathologic features in Uruguayan BC patients (pts). Methods: We retrospectively reviewed clinical records from pts who underwent curative surgery for stage I-III invasive BC at the Oncology Units of 4 institutions in Montevideo between march 2006 and march 2008. We obtained the following data: age, TNM, ER/PR status by immunohistochemistry (IHC) and HER2 status by IHC and FISH in HER2 IHC 2+. Fisher's exact test was used to analyze the data. Results: 427 pts were included. Median age was 60 years-old (range: 24–93 y), postmenopausal 75%, stages: I 33%, II 42%, III 23%, unknown 2%. ER/PR status was known in 94,6% of cases: ER+/PR+ 66,1%, ER+/PR- 11,1%, ER-/PR+ 3,5%, ER-/PR- 19,3%. HER2 status was known in 47% (199/427) of cases, being positive (IHC 3+ or FISH+) in 13.6%. Triple negative tumors were found in 32 of 199 pts (16%). HER2 was positive in 8% of pts with ER+ and/or PR+ tumors, and in 18% of pts with ER-PR- disease (p=0.08). We did not find a significant association between axillary lymph node status and HER2 status. Besides, triple negative BC did not correlate with axillary lymph node status. When analized by menopausal status, the frequency of triple negative pts was 14% in the premenopausal group and 4% in the postmenopausal group (p=0.005). In addition, the rate of triple negative BC was 0% in pts with histologic grade 1 and 10% in pts with histologic grade 2–3 (p = 0.0005). Conclusions: Our data from Uruguayan pts show a lower prevalence of HER2 positive but a similar prevalence of ER+ and PR+ operable BC than the prevalence reported in most American and European studies. In accordance with previous reports, triple negative BC correlated with younger age and higher histologic grade. No significant financial relationships to disclose.

scholarly journals Correlation of Serum HER-2/neu Levels with Clinico-Pathological Variables and Tissue Immunohistochemistry in Breast Carcinoma

2021 ◽  
Vol 6 (1) ◽  
pp. 18-24
Author(s):  
Islam Barkatullah ◽  
Syed Shamshad Ahmad ◽  
Kafil Akhtar ◽  
Tariq Mansoor
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Tumour Size ◽  
Metastatic Breast ◽  
Prognostic Indicators ◽  
Lymph Node Status ◽  
Preoperative Serum ◽  
Invasion Stage ◽  
Size Grade ◽  
Her 2

Introduction: Serum levels of HER-2/neu protein is raised in primary as well as metastatic breast cancer and decreased serum HER-2/neu concentration in patients treated with HER- 2/neu inhibitors like trastuzumab is a good prognostic indicator in metastatic cases. Aims: To evaluate the concordance of serum HER-2/neu concentration with tissue HER-2/neu immunohistochemistry and determine its relationship with various prognostic indicators like age, size of tumour, lymph node status, grade, and stage of tumour. Materials and methods: The preoperative serum samples of 56 clinically and cytologically diagnosed cases of breast carcinoma were taken and postoperative mastectomy specimens were examined for the histologic type, lympho-vascular invasion, stage, and grade of the tumour. Immunohistochemical study of HER-2/neu xpression and HER-2/neu serum biochemistry was studied. Results: Age of the patients ranged from 25-75 years. Twenty-three cases (41.1%) were premenopausal while 33 cases (58.9%) postmenopausal. Forty-seven cases (83.9%) were of the infiltrating ductal carcinoma (NOS) type. Serum positivity for HER-2/neu was noted in 29 (51.8%) cases. Serum HER-2/neu levels showed a positive correlation with increase in tumour size, grade, stage of tumour and lymph node involvement. Serum HER-2/neu positivity was seen in 20 (68.9%) IHC positive patients and 9 (33.3%) IHC negative patients, with a statistically significant correlation (p=0.005). Conclusions: Serum HER-2/neu levels directly correlate with prognostic factors like tumour size, grade, stage of the tumour and lymph node metastasis and can be used as a complimentary tool to tissue HER-2/neu immunohistochemistry.

Correlation of Histologic Grade and Lymph Node Status with Some Histopathologic Discriminants in Breast Cancer

1986 ◽  
Vol 72 (1) ◽  
pp. 43-51 ◽  
Author(s):  
Mariano Urdiales-Viedma ◽  
Francisco Nogales-Fernandez ◽  
Sebastian Martos-Padilla ◽  
Emilio Sanchez-Cantalejo
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Histologic Grade ◽  
Lymph Node Status ◽  
Node Status

scholarly journals Comparison of ER, PR, Ki67 and HER-2/neu Reactivity Pattern with Patients’ Age, Histologic Grade, Tumor Size and Lymph Node Status in Invasive Ductal Breast Cancer

2020 ◽  
Vol 13 (6) ◽  
Author(s):  
Mahsa Ahadi ◽  
Motahareh Heibatollahi ◽  
Sara Zahedifard
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Tumor Size ◽  
Histological Grade ◽  
Lymph Node Involvement ◽  
Lymph Node Status ◽  
Invasive Ductal Breast Cancer ◽  
Ductal Breast Cancer ◽  
Node Involvement ◽  
Her 2

Background: Breast cancer is the most prevalent neoplasm diagnosed in Iranian women. Objectives: The current study was performed to measure the hormone receptor status and its possible connection with the patient’s age, tumor size, histological grade, and lymph node status and involvement in patients with invasive ductal breast cancer (IDBC) Methods: A total of 103 women with IDBC recently diagnosed at the Department of Pathology of Shohada-E-Tajrish Hospital were entered into this study. The mean age of the patients was 48.4 years, and 59.2% of cases were 50 years old or less. Results: Most lesions (78.6%) were more than 2 cm at their greatest dimension. Grade-II lesions were observed in a large number of patients and 59.8% of cases had lymph node involvement. Positive ER, PR, and HER-2/neu were detected in 59%, 57%, and 29% of patients, respectively. A significant correlation was found between patients’ age and histologic score, tumor dimension and both histologic score and nuclear grade, and, finally, between lymph node involvement and nuclear grade. Conclusions: According to previous studies, the evaluation of hormone receptor status in patients with breast cancer is strongly recommended. Here, by studying its possible connection with the patient’s age, tumor size, histological grade, and lymph node metastasis, we detected some biomarkers, which could be used as prognostic indices in these patients. These biomarkers could help us in the clinical management of patients with IDBC by providing the best therapeutic options.

Synthesis and Clinical Development of Palbociclib: An overview

2020 ◽  
Vol 17 ◽  
Author(s):  
Debabrata Konar ◽  
Saurabh Maru ◽  
Subhabrata Kar ◽  
Kapil Kumar
Keyword(s):  
Breast Cancer ◽  
Acquired Resistance ◽  
Survival Rates ◽  
Metastatic Breast ◽  
The United States ◽  
Breast Cancers ◽  
Cancer Awareness ◽  
Primary Resistance ◽  
Awareness Campaigns ◽  
Active Research

: Breast cancer is the second most commonly identified cancer in women in the United States after skin cancer. The past few years have seen a substantial increase in breast cancer awareness campaigns and active research in fields of diagnosis and targeted therapy. These factors have led to a better mechanistic understanding of the disease, detection at earlier stages and more personalized approach to treatment, ultimately causing a crucial increase in the survival rates after detection. However, with the advances in treatment, cases of patients developing primary resistance and acquired resistance are increasing. Most of the breast cancers which develop resistance to therapy are ER+ and are typically treated with tamoxifen and fulvestrant. These drugs either lower the levels of estrogen or inhibit the receptors for estrogen and prevent the tumor from spreading. Around one third of women treated with these drugs develop resistance to them, lowering their chances of survival. This has directed to the search of newer drug therapies to target advanced breast cancer and resistance. One of these efforts has resulted in the development of Palbociclib, a first in class inhibitor of cyclin dependent kinases 4 and 6 (CDK4 and CDK6), which was granted accelerated approval from FDA for combination therapy in postmenopausal women with ER+, HER2- metastatic breast cancer. This review is focused on the various aspects of “Palbociclib” including its synthesis, molecular modeling studies and efficacy and safety profile with clinical trials data.

Clinical and pathological characteristics of basal -like breast carcinomas

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10768-10768
Author(s):  
F. Gago ◽  
D. R. Ciocca ◽  
B. Mendiondo ◽  
J. Orozco ◽  
O. Tello
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
P53 Protein ◽  
Premenopausal Women ◽  
Tumor Grade ◽  
Lymph Node Status ◽  
Control Group ◽  
Breast Carcinomas ◽  
Pathological Characteristics ◽  
Her 2

10768 Clinical and pathological characteristics of basal -like breast carcinomas. Background: Genetic studies have revealed different subtypes of breast carcinomas with particular molecular characteristics. Basal-like breast carcinomas are characterized by negative hormonal receptors and negative HER-2 receptor. We have compared basal-like breast carcinomas with a randomized control population selected from our data base of breast cancer. Methods: From 2127 breast invasive carcinomas, 716 were evaluated with immunohistochemical methods, considering the expression of estrogen receptors, progesterone receptor, HER-2 and p53 protein, between 1989 and 2005. According to the molecular classification the results were: 1) Luminal 398 (55.6%), 2) HER- 2 positive: 193 (26.9%) and 3) Basal-like 124 (17.5%). We retrospectively analyzed the age at diagnosis, menopausal status, tumor size, histological grade, histopathology, lymph node status, stage and the evolution of the breast cancer. The average follow-up was 66.2 months. The control group consisted of 170 patients. The statistical analysis was performed with chi-square test, Fisher’s test and the non parametric test of the Mac Nemar’s signs. Results: The median age at diagnosis was 52 years old. This is lower than the average age of the Tumor Register of Mendoza, that is 60 years (p: < 0.01). The basal-like carcinomas predominated in premenopausal women (p = 0.07), and had a higher proportion of high tumor grade (p ≤ 0.0001) and expression of p53 protein (p=0.01). There were not significant statistical differences concerning the tumor size, the lymph node status, histopathology, and the stage at presentation. The 5-year disease-free survival (DFS) of basal-like breast carcinomas was 71.7% and the 5-year overall survival (OS) was 83.3%. Whereas the DFS for the control group was 77.3% and the OS was 87.3%. Conclusions: The basal-like breast carcinomas are characterized by having a younger age at presentation, predominating in premenopausal women, and presenting a high tumor grade with overexpression of p53 protein. No significant financial relationships to disclose.

MALE BREAST CARCINOMA: A CASE REPORT

2021 ◽  
pp. 226-227
Author(s):  
Sarvesh Kumar Dubey ◽  
Subham Anand ◽  
D. K. Sinha ◽  
Aravind. K.R
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Positive Family History ◽  
Age Distribution ◽  
Male Breast ◽  
Age At Diagnosis ◽  
Prognostic Indicators ◽  
Lymph Node Status ◽  
Breast Cancers ◽  
Predisposing Factor

Male breast cancer(MBC) is a rare disease and represents less than 1% of all malignancies in men and only 1% of all breast cancers. The mean age at diagnosis for men with breast carcinoma is older than the average age at diagnosis for women. It has a unimodal age frequency distribution that peaks at age distribution of 71 years. MBC behaves in a way similar to post menopausal breast cancer in women. The main predisposing factor is a positive family history of breast cancer. 90% tumors are ER positive. The most important prognostic indicators are stage at diagnosis and lymph node status.

Sign in / Sign up

Export Citation Format

Share Document